Literature DB >> 23486123

Microsurgical head and neck reconstruction after oncologic ablation: a study analyzing health-related quality of life.

Arash Momeni1, Rebecca Y Kim, Ahlia Kattan, Gordon K Lee.   

Abstract

BACKGROUND: Evaluation of quality of life (QOL) measures is increasingly being valued as an essential parameter to determine treatment results after head and neck reconstruction. The present study was designed to evaluate the effect of microsurgical reconstruction on patient-reported QOL.
METHODS: Patients undergoing microsurgical reconstruction after radical oncosurgical ablation of head and neck malignancies from March 2007 to March 2010 were included in the study. To assess health-related QOL, the following questionnaires were sent to patients who met inclusion criteria: European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30 [Version 3.0]) and Head and Neck Cancer Quality of Life Questionnaire (QLQ-H and N35).
RESULTS: A total of 60 patients underwent microsurgical reconstruction of postablative head and neck defects during the study period. Twenty-one patients were successfully contacted, all of which completed the surveys. Satisfactory global QOL scores were achieved. Advanced age correlated with greater impairment for the ability to taste and smell (P = 0.05). Radiotherapy seemed to be associated with "sticky saliva"; although this was not statistically significant (P = 0.06). Recurrent disease at the time of surgical ablation and microsurgical reconstruction did not seem to have any appreciable impact on QOL. Finally, patients who developed postoperative complications had lower levels of "cognitive functioning" (P = 0.04), problems with "insomnia" (P = 0.04) and "social contact" (P = 0.03), and more commonly "felt ill" (P = 0.03).
CONCLUSIONS: Improved global QOL scores were observed after microsurgical reconstruction of various head and neck defects when compared to reported pretreatment scores. Of the parameters analyzed, it seems that postoperative complications have the most profound effect on items assessed with the EORTC QLQ-C30 and H and N35 surveys. Our findings provide further scientific evidence that patients with head and neck malignancy benefit from surgical intervention with respect to postoperative QOL.

Entities:  

Mesh:

Year:  2013        PMID: 23486123     DOI: 10.1097/SAP.0b013e31827737a5

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  5 in total

1.  Quality of life after free flap surgery for cancer of the head and neck in patients with or without postoperative complications.

Authors:  Sanna Lahtinen; Petri Koivunen; Tero Ala-Kokko; Päivi Laurila; Outi Kaarela; Janne H Liisanantti
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-24       Impact factor: 2.503

2.  Systematic review of negative pressure wound therapy for head and neck wounds with fistulas: Outcomes and complications.

Authors:  Fu-Yu Lin; Pin-Yi Huang; Hsu-Tang Cheng
Journal:  Int Wound J       Date:  2019-11-06       Impact factor: 3.315

Review 3.  Sinonasal Side Effects of Chemotherapy and/or Radiation Therapy for Head and Neck Cancer: A Literature Review.

Authors:  Giuseppe Riva; Ester Cravero; Claudia Pizzo; Marco Briguglio; Giuseppe Carlo Iorio; Chiara Cavallin; Oliviero Ostellino; Mario Airoldi; Umberto Ricardi; Giancarlo Pecorari
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

4.  Does Medication-Related Osteonecrosis of the Jaw Influence the Quality of Life of Cancer Patients?

Authors:  Gianluca Tenore; Ahmed Mohsen; Antonella Francesca Rossi; Gaspare Palaia; Federica Rocchetti; Andrea Cassoni; Valentino Valentini; Livia Ottolenghi; Antonella Polimeni; Umberto Romeo
Journal:  Biomedicines       Date:  2020-04-24

5.  Predictors of Oral Function and Facial Aesthetics Post Maxillofacial Reconstruction with Free Fibula Flap.

Authors:  Ahmed Alotaibi; Abdulsalam Aljabab; Ghazi Althubaiti
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.